Oral semaglutide compared to Januvia in patients with type 2 diabetes
Oral
Semaglutide powder
7 mg and 14 mg demonstrated superior HbA1c and body weight reductions
compared to Januvia (sitagliptin 100 mg) . Non-inferiority for oral
semaglutide 3 mg for HbA1c reductions at 26 weeks was not confirmed.
Presented at the Endocrine Society Annual Meeting in New Orleans,
Louisiana, with simultaneous publication in the Journal of the American
Medical Association (JAMA).
PIONEER 3 was a phase IIIa trial investigating the efficacy and
long-term safety of oral semaglutide 3 mg, 7 mg and 14 mg compared with
sitagliptin 100 mg in adults with type 2 diabetes inadequately
controlled with metformin, with or without sulfonylurea, over 78 weeks.
Oral semaglutide is an investigational once-daily glucagon-like
peptide-1 (GLP-1) analogue in a pill.
In PIONEER 3 , the primary endpoints of HbA1c and confirmatory
secondary endpoint of change in body weight were assessed after 26 weeks
of treatment. When applying the primary statistical approach, oral
semaglutide 7 mg and 14 mg demonstrated superior HbA1c reductions of
1.0% and 1.3% at 26 weeks, compared to a 0.8% reduction with sitagliptin
(both p
The Wall